 SEATTLE, Dec. 05, 2022 GLOBE NEWSWIRE -- Adaptive Biotechnologies Corporation Nasdaq: ADPT, together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptives next-generation sequencing NGS-based clonoSEQ Assay in measuring minimal residual disease MRD in blood cancer patients at the 64th Annual Meeting of the American Society of Hematology ASH taking place December 10-13, 2022. 